BioTransplant Selected as One of 25 Companies Worldwide to Participate in Discovery Expo '99, August 19th in Chicago.CHICAGO--(BUSINESS WIRE)-- BioTransplant Incorporated (Nasdaq: BTRN) will be among 25 growth companies to gather August 19th at Discovery Expo '99 to meet fund managers, analysts, stockbrokers and investors at The Midland Hotel. The Company, based in Charlestown, Mass., is developing pharmaceuticals and systems which are designed to re-educate re·ed·u·cate also re-ed·u·cate tr.v. re·ed·u·cat·ed, re·ed·u·cat·ing, re·ed·u·cates 1. To instruct again, especially in order to change someone's behavior or beliefs. 2. the body's immune system immune system Cells, cell products, organs, and structures of the body involved in the detection and destruction of foreign invaders, such as bacteria, viruses, and cancer cells. Immunity is based on the system's ability to launch a defense against such invaders. to accept foreign cells, tissues and organs, creating potentially valuable new treatments for organ transplantation The transfer of organs such as the kidneys, heart, or liver from one body to another. The transplantation of human organs has become a common medical procedure. Typical organs transplanted are the kidneys, heart, liver, pancreas, cornea, skin, bones, and lungs. and cancers. BioTransplant's lead product, MEDI-507, is currently in multiple Phase II trials for treatment of graft-versus-host disease graft-versus-host disease n. A type of incompatibility reaction of transplanted cells against host tissues that possess an antigen not possessed by the donor. Also called graft-versus-host reaction. (GvHD), an often fatal outcome of bone marrow transplants. MEDI-507 is being developed in collaboration with MedImmune, Inc. The Company's AlloMune(TM) Systems, for human organ transplantation and blood cell cancers, are scheduled to begin initial human testing in 1999. The Company's XenoMune(TM) System, a system for cross-species organ transplantation, is in preclinical testing. BioTransplant has corporate collaborations with MedImmune and Novartis Pharma AG, as well as a range of scientific collaborators, including the Massachusetts General Hospital Massachusetts General Hospital Health care The major teaching hospital for Harvard Medical School, widely regarded as one of the best health care centers in the world (MGH MGH Massachusetts General Hospital MGH McGraw-Hill Companies MGH Montreal General Hospital (Montreal, Canada) MGH Monumenta Germania Historica MGH May Go Home MGH Minneapolis General Hospital ). BioTransplant Incorporated utilizes its proprietary technologies in re-educating the body's immune responses to allow tolerance of foreign cells, tissues and organs. Based on this ImmunoCognance(TM) technology, the Company is developing a portfolio of products designed to treat a range of medical conditions, including organ and tissue transplantation, cancer and autoimmune disease, for which current therapies are inadequate. BioTransplant's products are intended to induce long-term functional transplantation tolerance in humans, increase the therapeutic benefit of bone marrow transplants, and reduce or eliminate the need for lifelong immunosuppressive therapy. The Expo brings together undiscovered companies with high-profile growth fund managers, analysts, stockbrokers and sophisticated investors in a one-day event. These key players will have a chance to become acquainted with the products, top executives and future outlook of participating Nasdaq and OTC Bulletin Board OTC Bulletin Board An electronic quotation listing of the bid and asked prices of OTC stocks that do not meet the requirements to be listed on the NASDAQ stock-listing system. listed firms whose stock represents opportunities for appreciation. For more information on attending, visit www.w3otc OTC See: Over-the-counter. OTC See over-the-counter market (OTC). .com/tirweb/expo99/at-summer-99-c.htm, E-mail w3otc@w3otc.com, or call 949-724-0444. For more information on BioTransplant visit www.biotransplant.com |
|
||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion